Sector News

Incoming St. Jude medical president and CEO Mike Rousseau announces executive leadership team

September 15, 2015
Life sciences

(BUSINESS WIRE) – St. Jude Medical, Inc. today announced the new executive leadership team that incoming President and Chief Executive Officer (CEO) Michael T. Rousseau has chosen to lead the organization into the next phase of growth and innovation. Effective Jan. 1, 2016, the new team alignment leverages the Company’s deep bench of talent and ensures the continuity of key leadership positions within St. Jude Medical.

“We are fortunate to have an executive team that’s uniquely qualified to continue St. Jude Medical’s growth story,” Rousseau said. “This is a remarkable team with a diverse set of experiences and a proven track record that will allow us to continue to transform and diversify the way we develop medical technologies in order to improve the care for patients around the world. Over the past several years, our executive team has made significant contributions to the business and shares in the excitement of the future of St. Jude Medical.”

The executive leadership team will include a new structure intended to drive organizational effectiveness and maximize the depth of experience of St. Jude Medical leaders. No changes, other than one addition, will be made to the current roster of St. Jude Medical Executive Officers. The following officers will report to Rousseau, effective Jan. 1, 2016:

Source: St. Jude Medical

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”